BPC-157 and Alcohol Damage: Checking the 2021 Rat Study Claim

Key points

• The post describes a 2021 study in male rats, not people. The rats received a large dose of 96% alcohol straight into the stomach under deep anaesthesia, and effects were followed for up to 30 minutes after a single BPC 157 injection [1][2].
• The paper reports that BPC 157 “markedly” reduced stomach lesions and reversed or counteracted many vascular, brain, heart and lung findings. Some outcomes are described as fully counteracted, others as marked or partial [2].
• The gene work was a three-gene qPCR panel at 5 minutes. Expression went down in several organs as well as up in one, and the authors call the mechanism unresolved [2].
• Of 25 PubMed records mentioning BPC-157 and alcohol or ethanol, 24 include P. Sikirić, the senior author of this paper. We found no independent replication [3][4].
• No human data exist for this model. BPC-157 is not an approved medicine in the US and is prohibited in sport under WADA class S0 [6][7][11].

What does the post claim?

The X post by @thesupermannx (2026-11-09) says “scientists found a peptide that reverses alcohol damage across the entire body in under 30 minutes.” It adds that “they used 96% alcohol to induce massive, systemic damage in subjects,” that BPC-157 “completely counteracted it” through an “innate ‘cytoprotective’ effect that rapidly repaired the vascular system in real-time,” and that researchers “tracked it all the way down to the gene expression level.” The attached image is the first page of the paper [1]. A post is a claim, not evidence, so each statement is tested below.

What did the alcohol study actually test?

The paper is Gojković S, Krezić I, Vranes H and colleagues (Sikirić P is the last author), University of Zagreb, “Robert’s Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157,” Biomedicines 2021, 9(10):1300, open access, doi 10.3390/biomedicines9101300 [2].

Design as reported in the full text [2]:

• Animals: male albino Wistar rats, 12 weeks old, about 200 g. Females were not used.
• Injury: 1 mL of 96% alcohol delivered into the stomach under deep anaesthesia.
• Treatment: one minute later, BPC 157 or an equal volume of saline was injected into the abdominal cavity. Two BPC 157 dose levels were compared.
• Timing: animals were assessed 1 minute after alcohol (before treatment) and then 1, 5, 15 or 30 minutes after treatment. The paper says the rats were euthanised at these intervals.
• Group size: “randomly assigned at six rats/group/interval.” The paper gives no total animal number in the passages we read.
• Outcomes: the share of glandular stomach covered by haemorrhagic lesions; pressure in the brain’s superior sagittal sinus, portal vein, vena cava and aorta; vein and brain swelling; clot (thrombus) mass; ECG; and scored histology of stomach, brain, lung, heart, liver and kidney.
• Statistics: ANOVA with Newman-Keuls, or Kruskal-Wallis with Mann-Whitney tests, and chi-square or Fisher tests for frequencies; p < 0.05.
• Blinding: “The experiments were assessed by observers blinded to the treatment.”
• Funding and conflicts: supported by the University of Zagreb (grant BM 099); the authors declare no conflicts of interest. The study was approved by a local ethics committee.

Limitations are thin. The Discussion says animal studies “must be interpreted with caution,” that clinical BPC 157 data are scarce, and that the extent and mechanisms of benefit “remain to be fully explored” [2]. We did not find a dedicated limitations section in the part we read.

What does the paper report for BPC 157 versus control?

Compared with saline-treated alcohol rats at the same interval, the authors report [2]:

• Stomach: lesions “markedly attenuated.” This is not stated as complete.
• Brain: swelling reversed, sinus pressure back to negative values, and structurally normal cortex and hippocampus on histology. At 30 minutes the text mentions only minimal oedema.
• Veins and pressures: portal and caval hypertension and aortic hypotension resolved; the failed azygos vein was reversed; thrombosis “markedly counteracted and reversed.”
• Heart: dilatation counteracted; ST elevation “completely counteracted”; other ECG changes “markedly counteracted.”
• Lung, liver, kidney: mild lung congestion at 15 and 30 minutes without haemorrhage; no liver or kidney changes at 30 minutes reported.

We did not read the figures, so we cannot give the lesion percentages or effect sizes. The text we read has no separate no-alcohol group followed over the same time course; comparisons are to saline-treated alcohol rats and to healthy-rat reference values [2].

Is the “under 30 minutes” claim true?

Partly. The study’s last time point is 30 minutes after treatment, so reported effects fall within that window in anaesthetised rats [2]. The abstract says BPC 157 counteracted the deficits “rapidly” and gives no human time frame. The design appears to use different rats for each interval, so it is a series of snapshots, not one animal tracked “in real-time.” We infer this from “six rats/group/interval” and the euthanasia statement; we did not confirm it from the figures [2].

Was the study done in humans?

No. The paper is a rat study from a single university group [2]. None of the 25 PubMed titles that mention BPC-157 and alcohol or ethanol describes a human study [4]. A 2026 systematic review (searches to 1 June 2026) found three human BPC-157 studies in total, 30 people, with no control groups and “very low” certainty, covering knee pain, interstitial cystitis and an intravenous safety check, and none involved alcohol [8]. We re-opened one registered trial: a 120-person phase 2 trial in hamstring strain, industry-sponsored, randomised and quadruple-masked, recruiting since 2026-02-02, with no results posted [9]. For the wider human record see our BPC-157 evidence article.

Was the gene-expression claim in this paper?

Yes, in a limited form. The paper reports qPCR for three genes (Nos3/eNOS, Mtor and Vegfa) in heart, stomach, kidney, lung, brain and liver, taken 5 minutes after alcohol, with one of the two BPC 157 dose levels [2]. Reported changes were mixed: eNOS fell in stomach and liver and rose in lung; mTOR fell in heart, lung, brain and liver; VEGFa fell in heart, stomach and liver and rose in lung; several others were unchanged. The authors say these changes “may illustrate” points at which BPC 157 worked and describe the mechanism as unresolved [2]. That is a three-gene snapshot, not an unbiased gene-expression survey, and most reported changes are decreases.

Who is behind the literature, and has it been replicated?

A PubMed search on 2026-11-09 for BPC-157, BPC157 or “body protection compound” in titles and abstracts returned 234 records. Sikirić is first or last author on 148 and an author on 176 (we matched author names after removing diacritics) [3]. A narrower search for BPC-157 together with alcohol or ethanol in title or abstract returned 25 records; 24 list Sikirić as an author, including the 2004 and 2006 mouse papers and 2001 rat papers from the same Zagreb group. The remaining record is a 2026 paper on producing small peptides in bacteria, by its title not an alcohol-injury study [4]. Europe PMC returned 95 hits for the same terms; by title and author list we saw no alcohol-injury study from an unrelated group, though a 2020 NSAID paper includes Korean authors alongside Sikirić [5].

We found no independent replication of the alcohol model. That is a limit of title-and-author screening, not proof that none exists.

Verdict table

Claim in the post	What the paper shows	Verdict
“Scientists found a peptide … they published a paper”	Paper published 2021-09-23 by the Zagreb group (Sikirić senior author); BPC 157 dates from that group’s earlier work, not a new finding [2][3]	Partly supported (old, single group)
“Reverses alcohol damage across the entire body”	Examined stomach, brain, veins, heart, lung, liver, kidney, in male rats only [2]	Partly supported (rats, six organs/systems)
“In under 30 minutes”	Assessments up to 30 minutes after treatment in anaesthetised rats [2]	Partly supported (animal time frame)
“Subjects”	Rats, not people [2]	Not supported if read as people
“Completely counteracted”	Stomach “markedly attenuated”; some outcomes described as complete (for example ST elevation), others marked [2]	Partly supported
“Rapidly repaired the vascular system in real-time”	Vessel pressures and swelling at 1-30 minutes in different rats per interval; “innate” mechanism not tested directly [2]	Partly supported
“Tracked down to gene expression”	qPCR for three genes at 5 minutes, mixed direction, mechanism unresolved [2]	Not supported as worded
“Independent confirmation” (implied)	We found none [3][4][5]	Could not be verified

Regulatory status

United States (checked 2026-11-09). FDA’s compounding page (content current as of 2026-04-22) lists BPC-157 among substances nominated for compounding but withdrawn, previously in category 2, and says compounded BPC-157 may pose a risk of immunogenicity for certain routes and that FDA lacks enough information to know whether it causes harm in humans [6]. FDA’s category list updated 2026-05-14 does not name BPC-157 in categories 1, 2 or 3 (we searched the text) [10]. ABC News reported that on 2026-07-23 FDA’s Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, in favour of adding BPC-157 to the compounding list; the vote is non-binding and needs FDA sign-off [11]. We found no final FDA decision and did not open FDA’s meeting record. We found no approved medicine containing BPC-157. Approval, a compounding listing and a “research” label are different things.

Sport. WADA’s 2026 Prohibited List, valid from 2026-01-01, names BPC-157 as an example in class S0 (substances without approval for human therapeutic use), prohibited at all times; we read it in a copy hosted by a third party [7]. We did not open the 2027 list.

EU, UK, Germany. Not checked.

“Research use only.” It is a seller’s label, not a legal category. In a 2026-03-31 warning letter to a different seller (retatrutide and tirzepatide, not BPC-157) FDA said it judged intended use from the firm’s own promotion despite “Research Use Only” labelling [12]. Our legality overview sets out the wider picture. For what a lab report can and cannot show about a product, see what a peptide CoA proves, Janoshik test reports explained and reading a certificate of analysis.

Risks and unknowns

• No human data on this model. Nothing we found tests BPC-157 in people exposed to alcohol [4][8].
• The model is not drinking. The rats received a large amount of 96% alcohol into the stomach while deeply anaesthetised and were assessed within minutes. Human alcohol use over hours, days or years, with food, metabolism and withdrawal, is a different situation [2].
• Nothing here suggests safety. No result in this paper or in our sources suggests that any peptide or product makes drinking safe or treats alcohol harm. Anyone worried about alcohol poisoning, dependence or injury needs medical care, not a research peptide.
• Single group, male rats, short follow-up. Sex differences, longer outcomes and survival were not examined in the text we read [2].
• Human safety is thinly documented. The only human studies are three small uncontrolled reports of 30 people in total [8].
• Product quality. A research-use label says nothing about identity or purity; see the CoA articles linked above.

What the study cannot tell a reader

It cannot say whether BPC-157 would do anything in a person, at any dose, after any amount of alcohol. It cannot say whether the results hold outside the Zagreb group, in females, or beyond 30 minutes. It cannot say that the changes in three genes cause the observed effects.

Prices for this research peptide are on the BPC-157 compound page.

Frequently asked questions

Does BPC-157 reverse alcohol damage? In one 2021 rat study the authors report that it counteracted many alcohol-induced stomach, vascular, brain and heart findings within 30 minutes, some fully and some partly [2]. No human evidence exists and we found no independent replication [4][5].

What did the alcohol study actually test? Male rats received alcohol into the stomach under anaesthesia and then one injection of BPC 157 or saline, with measurements 1 to 30 minutes later and six rats per group per interval [2].

Was the study done in humans? No. The post’s word “subjects” meant rats [2]. A 2026 review found only three small human BPC-157 studies, none on alcohol [8].

Is the “under 30 minutes” claim true? Only as a statement about anaesthetised rats whose last time point was 30 minutes after treatment [2]. It says nothing about people.

Has the study been replicated? We found none. Of 25 PubMed records on BPC-157 and alcohol or ethanol, 24 include Sikirić as an author [4].

Is BPC-157 approved or legal? We found no approved medicine in the US. FDA’s compounding status is unresolved after a non-binding 8-6 committee vote on 2026-07-23, and WADA prohibits it in S0 [6][7][11]. We did not check EU, UK or German rules.

Sources

1. @thesupermannx, X post (2026-11-09), post text read through the fxtwitter mirror (X itself was not opened); the attached image was not viewed by us. https://x.com/thesupermannx/status/2119836233606320602
2. Gojković S, Krezić I, Vranes H et al., “Robert’s Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157”, Biomedicines 9(10):1300 (2021-09-23), full text on PubMed Central (PMC8533388). doi 10.3390/biomedicines9101300. https://doi.org/10.3390/biomedicines9101300
3. NCBI PubMed, search “BPC-157 OR BPC157 OR body protection compound” in title/abstract, run through E-utilities and counted by us (2026-11-09; 234 records). https://pubmed.ncbi.nlm.nih.gov/?term=BPC-157%5Btiab%5D+OR+BPC157%5Btiab%5D+OR+%22body+protection+compound%22%5Btiab%5D
4. NCBI PubMed, search for BPC-157 or BPC 157 with alcohol or ethanol in title/abstract, run through E-utilities, titles and author lists screened by us (2026-11-09). https://pubmed.ncbi.nlm.nih.gov/?term=%28BPC-157%5Btiab%5D+OR+BPC157%5Btiab%5D+OR+%22BPC+157%22%5Btiab%5D%29+AND+%28alcohol%5Btiab%5D+OR+ethanol%5Btiab%5D%29
5. Europe PMC REST search for “BPC 157” or “BPC-157” with alcohol or ethanol (2026-11-09; 95 hits; titles and author strings screened). https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28%22BPC%20157%22%20OR%20%22BPC-157%22%29%20AND%20%28alcohol%20OR%20ethanol%29&format=json
6. FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” (content current as of 2026-04-22). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
7. World Anti-Doping Agency, “The 2026 Prohibited List” (valid 2026-01-01), read in a copy hosted by Asia Rugby because we did not open wada-ama.org. https://www.asiarugby.com/wp-content/uploads/2026/06/2026list_en_final_clean_september_2025.pdf
8. Poolton JT, Minett J, Kazmi A, “Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety”, Acta Orthop Belg (2026-10-08); abstract read through PubMed E-utilities (PMID 42885452). https://pubmed.ncbi.nlm.nih.gov/42885452/
9. ClinicalTrials.gov, NCT07437547, “BPC 157 for Acute Hamstring Muscle Strain Repair” (queried 2026-11-09 through the registry API). https://clinicaltrials.gov/study/NCT07437547
10. FDA, “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act” (updated 2026-05-14), downloaded and text-searched by us. https://www.fda.gov/media/94155/download
11. ABC News, “FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list” (2026-07-23). https://abcnews.com/Health/fda-advisory-committee-votes-add-popular-peptide-bpc/story?id=134913891
12. FDA, Warning Letter to Gram Peptides, 721806 (2026-03-31). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026

Not verified and not cited as fact: the paper’s figures and the last ~1,600 characters of its page; the MDPI page itself (returned 403); FDA’s meeting record and briefing document; a search-result report of an FDA staff view on BPC-157 and ulcerative colitis, and a conflicting 6-7 vote claim on a clinic blog, both seen only as snippets; EMA, MHRA and BfArM registers.

This article is information, not medical advice.